Encapsulated amyloid-beta peptides

Details Encapsulated amyloid-beta peptides Encapsulated amyloid-beta peptides

2008-02-29

2009-11-17

Tsang, Cecilia (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S013800, C514S015800, C514S017400, C514S772300, C514S773000

Reexamination Certificate

active

07618944

ABSTRACT:
The present invention relates to the field of polymer chemistry and more particularly to encapsulated peptides and uses thereof.

REFERENCES:
patent: 5387742 (1995-02-01), Cordell
patent: 5854204 (1998-12-01), Findeis et al.
patent: 6455308 (2002-09-01), Freier
patent: 6670399 (2003-12-01), Green et al.
patent: 6761888 (2004-07-01), Schenk
patent: 6875434 (2005-04-01), Schenk
patent: 6890535 (2005-05-01), Schenk
patent: 6905686 (2005-06-01), Schenk
patent: 6972127 (2005-12-01), Schenk
patent: 7060671 (2006-06-01), Stott
patent: 7135181 (2006-11-01), Jensen et al.
patent: 7179892 (2007-02-01), Basi et al.
patent: 7189819 (2007-03-01), Basi et al.
patent: 7479550 (2009-01-01), Rosenberg et al.
patent: 2003/0086938 (2003-05-01), Jensen et al.
patent: 2003/0157117 (2003-08-01), Rasmussen et al.
patent: 2004/0043935 (2004-03-01), Frangione et al.
patent: 2005/0123553 (2005-06-01), Monsonego et al.
patent: 2006/0135403 (2006-06-01), Gervais et al.
patent: 2006/0142506 (2006-06-01), Breitenkamp et al.
patent: 2006/0172914 (2006-08-01), Breitenkamp et al.
patent: 2006/0240092 (2006-10-01), Breitenkamp et al.
patent: 2007/0010435 (2007-01-01), Frangione et al.
patent: 2007/0041945 (2007-02-01), Jensen et al.
patent: 2007/0098721 (2007-05-01), Hillen et al.
patent: 2007/0197452 (2007-08-01), Mclaurin
patent: 2007/0218491 (2007-09-01), Vasan et al.
patent: 2008/0207913 (2008-08-01), Breitenkamp et al.
patent: 2009/0092554 (2009-04-01), Skaff et al.
patent: WO/01/62284 (2001-08-01), None
patent: WO/03/015812 (2003-02-01), None
patent: WO/2004/018997 (2004-03-01), None
patent: WO/2004/024090 (2004-03-01), None
patent: WO/2007/064917 (2007-06-01), None
patent: WO/2008/098371 (2008-08-01), None
Bakar, N. K. A., et al., “The Chemical Speciation of Zinc in Human Saliva: Possible Correlation with Reduction of the Symptoms of the Common Cold Produced by Zinc Gluconate-Containing Lozenges”, Chem. Spec. Bioavail. 1999, 11, 95-101.
Eby, G. A., “Zinc Ion Availability- the Determinant of Efficacy in Zinc Lozenge Treatment of Common Colds”, J. Antimicrob. Chemo. 1997, 40, 483-493.
Cannan, R. K., et al, “Complex Formation Between Carboxylic Acids and Divalent Metal Cations”, A. J. Am. Chem. Soc. 1938, 60, 2314-2320.
Kolb, H. C. et al., “In Situ Click Chemistry: Enzyme Inhibitors Made to Their Own Specifications”, Chem. Int. Ed. 2001, 40, 2004-2021.
Wang, Q., et al., “Bioconjugation by Copper(1)-Catalyzed Azide-Alkyne [3+2] Cycloaddition”, J. Am. Chem. Soc. 2003, 125, 3192-3193.
Link, A. J. et al. , “Presentation and Detection of Azide Functionality in Bacterial Cell Surface Proteins”, J. Am. Chem. Soc. 2004, 126, 10598-10602.
Deiters, A., et al., Adding Amino Acids with Novel Reactivity to the Genetic Code of Saccharomyces Cerevisiae, J. Am. Chem. Soc. 2003, 125, 11782-11783.
Allen, C., et al., “Nano-engineering Block Copolymer Aggregates for Drug Delivery”, Colloid Surface B 1999, 16, 3-27.
Walsh, D. M. and D. J. Selkoe, “Deciphering the Molecular Basis of Memory Failure in Alzheimer's Disease”, Neuron, 2004. 44(1): pp. 181-93.
Morgan, D., et al., “Aβ Peptide Vaccination Prevents Memory Loss in an Animal Model of Alzheimer's Disease”, Nature, 2000. 408(6815): pp. 982-5.
Bard, F., et al., “Peripherally Administered Antibodies Against Amyloid β-Peptide Enter the Central Nervous System and Reduce Pathology in a Mouse Model of Alzheimer Disease”, Nat Med, 2000. 6(8): pp. 916-9.
Dickey, C. A., et al., “Selectively Reduced Expression of Synaptic Plasticity-Related Genes in Amyloid Precursor Protein + Presenilin-1 Transgenic Mice”, J Neurosci, 2003. 23(12): pp. 5219-26.
Morgan, D., “Antibody Therapy for Alzheimer's Disease”, Expert Rev Vaccines, 2003. 2(1): pp. 53-9.
Bayer, A. J., “Evaluation of the Safety and Immunogenicity of Synthetic Aβ42 (AN1792) in Patients with AD”, et al., Neurology, 2005. 64(1): pp. 94-101.
Mathews, P. M., et al., “Setback for an Alzheimer's Disease Vaccine Lessons Learned”, Neurology, 2003. 61(1): pp. 7-8.
Parihar, M. S., et al., “Alzheimer's Disease Pathogensis and Therapeutic Interventions”, J Clin Neurosci, 2004. 11(5): pp. 456-67.
Kirkitadze, M. D., et al., “Paradigm Shifts in Alzheimer's Disease and Other Neurodegenerative Disorders: The Emerging Role of Oligomeric Assemblies”, J Neurosci Res, 2002.69(5): pp. 567-77.
Chauhan, N. B., “Intracerebroventricular Passive Immunization With Anti-OligoAβ Antibody in TgCRND8”, J Neurosci Res, 2007. 85(2): pp. 451-63.
Nilsson, L. N., et al., “Cognitive Impairment in PDAPP Mice Depends on ApoE and ACT-Catalyzed Amyloid Formation”, Neurobiol Aging, 2004. 25(9): pp. 1153-67.
Zuliani, G., et al., “Plasma Cytokines Profile in Older Subjects With Late Onset Alzheimer's Disease or Vascular Dementia”, J Psychiatr Res, 2007. 41(8): pp. 686-93.
Abbas, N., et al., “Up-Regulation of the Inflammatory Cytokines IFN-γ and IL-12 and Down-Regulation of IL-4 in Cerebral Cortex Regions of APP SWE Transgenic Mice”, J Neuroimmunol, 2002. 126(1-2): pp. 50-7.

Affiliated with

Also associated with

Rating

Encapsulated amyloid-beta peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Encapsulated amyloid-beta peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Encapsulated amyloid-beta peptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4100877